News

Recursion Announces 10th Site Open for REC-994 Trial

August 12, 2022 –Recursion Pharmaceuticals has ten US sites enrolling cavernous malformation patients in Phase 2 of their REC-994 Sycamore trial. This is the first industry-sponsored trial of a medicine for cerebral cavernous malformations, a massive milestone toward better treatments. The ninth site to open is Valley Hospital in Ridgewood, New Jersey, under the direction…

Duke University Hospital Named Center of Excellence for Brain Malformation

Contact: Alexis Porter Phone: 919-695-2792 Email: alexis.porter@duke.edu http://dukehealthnews.org For Immediate Release: September 19, 2022 Duke University Hospital Named Center of Excellence for Brain Malformation Duke University Hospital has been selected as a Center of Excellence for the treatment of brain abnormalities called cerebral cavernous malformations (CCM) in both adults and children. The designation by the…